Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom.

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its rival pharmaceutical companies Eli Lilly’s stock surged 16% after the ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, sending shares in the US drugmaker up nearly 15 per cent in Wall Street ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...